Microdosing as a tool to individualize docetaxel dosing: development of a limited sampling model

Phase 4

Completed

• Conditions: Breast-; prostate and non-small cell lung cancer; 10027655

• Registration Number: NL-OMON49402
• Lead Sponsor: Meander Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Patients with breast-, prostate and non-small cell lung cancer (NSCLC), who are planned for routine treatment with docetaxel

Exclusion Criteria

Absence of informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics of a microdoce- and a therapeutic dose docetaxel</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Does not apply</p><br>